...
search icon
halo-img

Halozyme Therapeutics Inc, Common Stock

HALO

NSQ

$57.54

-$1.81

(-3.05%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.11B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
17.4257
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.88M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$37.73 L
$66 H
$57.54

About Halozyme Therapeutics Inc, Common Stock

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameHALOSectorS&P500
1-Week Return-7%-6.19%-10.13%
1-Month Return-6.35%-8.94%-10.08%
3-Month Return7.03%-4.24%-14.49%
6-Month Return6.3%-11.41%-12.01%
1-Year Return44.17%-5.81%-2.75%
3-Year Return37.23%-5.85%12.64%
5-Year Return225.27%42.58%84%
10-Year Return276.57%84.51%143.13%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue267.59M443.31M660.12M829.25M1.02B[{"date":"2020-12-31","value":26.36,"profit":true},{"date":"2021-12-31","value":43.66,"profit":true},{"date":"2022-12-31","value":65.02,"profit":true},{"date":"2023-12-31","value":81.67,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue43.37M81.41M139.30M192.36M159.42M[{"date":"2020-12-31","value":22.54,"profit":true},{"date":"2021-12-31","value":42.32,"profit":true},{"date":"2022-12-31","value":72.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":82.87,"profit":true}]
Gross Profit224.23M361.90M520.81M636.89M855.91M[{"date":"2020-12-31","value":26.2,"profit":true},{"date":"2021-12-31","value":42.28,"profit":true},{"date":"2022-12-31","value":60.85,"profit":true},{"date":"2023-12-31","value":74.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin83.79%81.64%78.90%76.80%84.30%[{"date":"2020-12-31","value":99.4,"profit":true},{"date":"2021-12-31","value":96.84,"profit":true},{"date":"2022-12-31","value":93.59,"profit":true},{"date":"2023-12-31","value":91.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses79.97M86.00M253.28M299.32M304.43M[{"date":"2020-12-31","value":26.27,"profit":true},{"date":"2021-12-31","value":28.25,"profit":true},{"date":"2022-12-31","value":83.2,"profit":true},{"date":"2023-12-31","value":98.32,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income144.25M275.90M267.53M337.57M551.48M[{"date":"2020-12-31","value":26.16,"profit":true},{"date":"2021-12-31","value":50.03,"profit":true},{"date":"2022-12-31","value":48.51,"profit":true},{"date":"2023-12-31","value":61.21,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(35.33M)(34.91M)(35.56M)(8.01M)(12.44M)[{"date":"2020-12-31","value":-3533100000,"profit":false},{"date":"2021-12-31","value":-3491000000,"profit":false},{"date":"2022-12-31","value":-3556000000,"profit":false},{"date":"2023-12-31","value":-800700000,"profit":false},{"date":"2024-12-31","value":-1243800000,"profit":false}]
Pre-Tax Income129.30M248.52M248.92M348.33M557.13M[{"date":"2020-12-31","value":23.21,"profit":true},{"date":"2021-12-31","value":44.61,"profit":true},{"date":"2022-12-31","value":44.68,"profit":true},{"date":"2023-12-31","value":62.52,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes217.00K(154.19M)46.79M66.73M113.04M[{"date":"2020-12-31","value":0.19,"profit":true},{"date":"2021-12-31","value":-136.4,"profit":false},{"date":"2022-12-31","value":41.39,"profit":true},{"date":"2023-12-31","value":59.04,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes129.09M402.71M202.13M281.59M444.09M[{"date":"2020-12-31","value":29.07,"profit":true},{"date":"2021-12-31","value":90.68,"profit":true},{"date":"2022-12-31","value":45.52,"profit":true},{"date":"2023-12-31","value":63.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations129.09M402.71M202.13M281.59M444.09M[{"date":"2020-12-31","value":29.07,"profit":true},{"date":"2021-12-31","value":90.68,"profit":true},{"date":"2022-12-31","value":45.52,"profit":true},{"date":"2023-12-31","value":63.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income129.09M402.71M202.13M281.59M444.09M[{"date":"2020-12-31","value":29.07,"profit":true},{"date":"2021-12-31","value":90.68,"profit":true},{"date":"2022-12-31","value":45.52,"profit":true},{"date":"2023-12-31","value":63.41,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)0.901.922.222.784.23[{"date":"2020-12-31","value":21.28,"profit":true},{"date":"2021-12-31","value":45.39,"profit":true},{"date":"2022-12-31","value":52.48,"profit":true},{"date":"2023-12-31","value":65.72,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HALO
Cash Ratio 4.29
Current Ratio 7.80
Quick Ratio 6.78

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HALO
ROA (LTM) 18.16%
ROE (LTM) 198.42%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HALO
Debt Ratio Lower is generally better. Negative is bad. 0.82
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.18

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HALO
Trailing PE 17.43
Forward PE 12.90
P/S (TTM) 7.22
P/B 20.29
Price/FCF 42
EV/R 8.17
EV/Ebitda 12.63
PEG NM

FAQs

What is Halozyme Therapeutics Inc share price today?

Halozyme Therapeutics Inc (HALO) share price today is $57.54

Can Indians buy Halozyme Therapeutics Inc shares?

Yes, Indians can buy shares of Halozyme Therapeutics Inc (HALO) on Vested. To buy Halozyme Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HALO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Halozyme Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Halozyme Therapeutics Inc (HALO) via the Vested app. You can start investing in Halozyme Therapeutics Inc (HALO) with a minimum investment of $1.

How to invest in Halozyme Therapeutics Inc shares from India?

You can invest in shares of Halozyme Therapeutics Inc (HALO) via Vested in three simple steps:

  • Click on Sign Up or Invest in HALO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Halozyme Therapeutics Inc shares
What is Halozyme Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Halozyme Therapeutics Inc (HALO) is $66. The 52-week low price of Halozyme Therapeutics Inc (HALO) is $37.73.

What is Halozyme Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Halozyme Therapeutics Inc (HALO) is 17.4257

What is Halozyme Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Halozyme Therapeutics Inc (HALO) is 20.29

What is the Market Cap of Halozyme Therapeutics Inc?

The market capitalization of Halozyme Therapeutics Inc (HALO) is $7.11B

What is Halozyme Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Halozyme Therapeutics Inc is HALO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top